CordenPharma has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide CDMO with facilities in North Augusta, South Carolina (USA) and Shanghai (China). With the acquisition, CordenPharma broadens its peptide API development and manufacturing capabilitiesfor complex peptide programs. The transaction expands CordenPharma’s upstream and […]
Post Type Archives: News
NorthX Biologics and enGenes Biotech cut recombinant protein development timelines by up to six months with integrated E. coli pathway
NorthX Biologics and enGenes Biotech have partnered to offer an integrated development and manufacturing pathway for recombinant protein programs in E. coli. The partnership addresses the disconnect between initial expression system development and GMP manufacturing, which saves early-stage programs three to six months in development time. The pathway helps biopharma developers reach clinical milestones faster, reducing scale-up […]
SK bioscience Signs Vaccine Technology Transfer Agreement with Colombia’s VECOL to Advance Local Vaccine Manufacturing in Latin America
SK bioscience announced that it has signed an agreement with Colombia’s state-owned pharmaceutical company VECOL for vaccine technology transfer and local manufacturing cooperation as part of Colombia’s national vaccine localization initiative. The initiative is jointly led by Colombia’s Ministry of Health and Social Protection, the National Health Institute (Instituto Nacional de Salud, INS), and VECOL, […]
Eli Lilly Acquires Engage Bio in $202 Million Deal
Engage Biologics, a biotechnology company advancing novel non-viral DNA delivery systems, announced that it had been acquired by Eli Lilly & Company on May 20th, 2026. According to a company press release, Lilly will pay up to $202 million in cash, including upfront and milestone payments, for the acquisition. Additional financial details were not disclosed […]
Lonza and Oxford Nanopore Technologies Launch Direct RNA Sequencing Solution for GMP mRNA Quality Control
Oxford Nanopore Technologies, a company delivering a new generation of nanopore-based molecular sensing technology, and Lonza today announced the launch of a new technology approach designed to modernize and accelerate GMP quality control testing for mRNA therapeutics. The solution combines direct RNA sequencing using nanopore technology with bespoke machine learning-based data analysis and customized software […]
Curia Completes Upgrade of API Aseptic Suites in Valladolid, Spain
Curia Global, Inc., a leading global research, development and manufacturing organization, today announced the completion of its upgrade to its two aseptic suites in Valladolid, Spain. The $4 million dollar investment is in accordance with the EU’s GMP Annex 1 standards. The central feature of the upgrade was the transition to a fully closed system, […]
Genentech Receives FDA Approval for Bladder Cancer Treatment
Genentech announced FDA approval of Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as an adjuvant treatment for muscle-invasive bladder cancer (MIBC) on May 15th, 2026. The treatment is indicated for adult patients who have circulating tumor DNA (ctDNA) molecular residual disease (MRD) after cystectomy. Atezolizumab is a monoclonal antibody designed to bind with PD-L1 […]
Bristol Myers Squibb and Tempus Announce Oncology and Neuroscience Collaboration
Tempus AI, a technology company advancing precision medicine through the practical application of AI, announced a new collaboration with Bristol Myers Squibb on May 14th, 2026. The new initiative aims to optimize clinical trial design and enhance the probability of technical and regulatory success via application of AI, multimodal real-world data, and data science techniques, […]
European Commission Expands Marketing Authorization for Pfizer Hemophilia Treatment
Pfizer announced that the European Commission granted a marketing authorization to expand the approved indication of Hympavzi (marstacimab) for the treatment of certain patients with hemophilia A or hemophilia B. The treatment is now indicated for patients with hemophilia A with FVIII inhibitors or hemophilia B with FIX inhibitors who are aged 12 or older […]
VoxCell BioInnovation and adMare BioInnovations Partner to Advance Novel Antibody Therapies in a Human-Relevant Vascularized Tissue Platform
VoxCell BioInnovation Inc. (“VoxCell”), a developer of bioprinted vascularized human tissue models for preclinical drug development, and adMare BioInnovations (“adMare”), Canada’s life sciences company creation engine, today announced a research partnership to validate the scientific and commercial potential of a novel antibody-based immune-modulating therapy using VoxCell’s human-relevant vascularized cancer tissue models. VoxCell’s platform brings together […]